Discover and read the best of Twitter Threads about #RoseBengalSodium
Most recents (8)
1/ $PVCT’s Modernized #SmallMolecule #RoseBengal: A #DrugSubstance, and #ActivePharmaceuticalIngredient for 21st Century #DrugDevelopment. A THREAD.
2/ “Everyone” seems to know or understand #RoseBengal, but do they (you) really?
3/ #RoseBengal is a small molecule (i.e., <1,000 Daltons*), but a “heavy” one at 973.67 Da or g/mol. It is heavy because of its four iodides, which comprise 52% of its molecular weight.
$PVCT-related medical journal article: DePalo DK, Zager JS. Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. Cancers. 2023; 15(5):1404. doi.org/10.3390/cancer…. @MoffittNews @USFHealthMed. Intralesional agent PV-10… twitter.com/i/web/status/1… 
Other $PVCT work by Dr. Zager (and Moffitt Cancer Center) as a principal investigator for us: PV-10 (#RoseBengalSodium) + #Keytruda (#pembrolizumab) for immune checkpoint blockade-naïve Stage III cutaneous melanoma
Other $PVCT work by Dr. Zager (and Moffitt Cancer Center) as a principal investigator for us: PV-10 (#RoseBengalSodium) + #Keytruda (#pembrolizumab) for immune checkpoint blockade-refractory advanced melanoma
1/ $PVCT’s PV-10 (#RoseBengalSodium) Immuno-Oncology Cycle & PD-1-Combination Mechanism. A #THREAD. #InduceAndBoost.
2/ Over the past decade-plus, cancer immunotherapy with antibodies targeting the PD-1 immune checkpoint pathway (i.e., PD-1 inhibitors #PD1) has yielded dramatic improvement in clinical outcome for many patients with #CutaneousMelanoma. #Keytruda #Opdivo #otherPD1s #PDL1s
3/ However, patients with Stage III disease and, in particular, those with in-transit disease (i.e., in-transit melanoma; ITM #IntransitMelanoma), have presented unique challenges with regard to response rate and durability of response.
1/ The impact of #Covid on $PVCT’s R&D, #DrugDiscovery, and clinical development of our #HalogenatedXanthene (#HX) medical science platform and #RoseBengalSodium (#RBS) investigational drug & drug formulation pipeline. A #THREAD.
2/ This $PVCT #thread will be an ongoing one for some time. Please check back to read it again (and again), and learn more about our medical scientific history and our lead molecule #RoseBengalSodium’s journey to becoming a multi-disease, broad-spectrum, therapeutic compound.
3/ #Covid has been a deeply painful experience, to say the least, for the U.S. and the world. It also marked a turning point in the advancement and expansion of our #HX medical science platform, as well as our lead molecule #RoseBengalSodium and the investigational drugs and drug… twitter.com/i/web/status/1…
1/ A $PVCT THREAD: (3) Potential 2023 read outs of preclinical data from sponsored research programs (#SRAs) in different diseases. #research. #oncology #hematology #dermatology #InfectiousDiseases #ophthalmology #WoundHealing #TissueRegeneration. #rosebengal #rosebengalsodium.
3/ In 2023, $PVCT expects research collaborators at different academic medical institutions to read out data from their preclinical research work under newly established and existing #SRAs. #research. #rosebengal #rosebengalsodium.
1/ A THREAD on what $PVCT achieved in 2022. #event #discovery #milestone #milepost. #rosebengal #rosebengalsodium.
3/ $PVCT #clinical and #research collaborators made 6 presentations at 5 medical conferences about PV-10 for different cancers. #ENETS22 #AACR22 #ASCO22 #ISOO2022 #melanomabridge. #presentations. #rosebengal #rosebengalsodium.
$PVCT Releases 2023 Stockholder Letter globenewswire.com/news-release/2… #rosebengal #rosebengalsodium
1/ $PVCT 2023 Shareholder Letter: (2) Design, prepare, and potentially commence a Phase 2/3 RCT of PV-10®+SOC checkpoint vs monotherapy SOC checkpoint ($MRK #keytruda, $BMY #opdivo) for 1st-line Stage III cutaneous melanoma. #rosebengal #rosebengalsodium. A THREAD.
2/ Utilizing clinical data from an ongoing, multi-cohort, Phase 1b/2 study of PV-10+checkpoint ($MRK #keytruda) for checkpoint-naïve metastatic melanoma (NCT02557321). #rosebengal #rosebengalsodium.
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigens from a defined library; PV-10 produces antigens present in an injected tumor that may extend beyond what's contained in the library
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA presumably is based on genomic profiling of a single tumor; PV-10 produces antigens specific to each injected tumor
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigens, but presumably does not produce co-stimulatory factors; PV-10 produces antigens + multiple co-stimulatory factors, such as DAMPs (damage-associated molecular patterns)
